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Paediatric mixtures
By Dr Alison Haywood and Professor Beverley Glass
solutions through compounding
Rationale for 
compounding medicines 
for children
In many practice settings, pharmacists 
are frequently challenged with 
providing a suitable formulation for 
patients who are unable to swallow 
solid dosage forms. Children often 
require titratable individualised doses 
in milligrams per kilogram of body 
weight and most children under six 
years of age cannot swallow tablets.1 
There are a limited number of 
suitable dosage forms commercially 
available for children, not only due to 
the size of the market but also the 
resulting lack of financial viability for 
the pharmaceutical industry of such 
dosage forms. In addition there are 
complexities associated with the 
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Learning objectives 
After reading this article you should 
be able to:
• Describe when compounding 
oral liquids to meet specific 
requirements for children is 
necessary, and the precautions 
to be taken by pharmacists in 
undertaking this task. 
• Describe compounded 
oral liquids, including the 
components, methods of 
preparation, packaging, storage 
and labelling. 
• Counsel patients/carers on 
the appropriate use of these 
compounded oral liquids.
Competencies addressed: 
4.2.2, 5.1.2, 5.1.3, 5.2.7
formulation of liquid dosage forms 
due to various physicochemical 
factors.2 The preparation of oral liquids 
extemporaneously by pharmacists, 
recently reviewed by Nahata3 
and Giam4, therefore provides an 
important solution to this problem 
for paediatric patients. This article 
will assist in informing pharmacists 
on the preparation of safe, stable oral 
liquids for children in those cases 
where suitable dosage forms are 
not available.
Compounding oral liquids
Active ingredient
In most practice settings, sourcing 
the active pharmaceutical ingredient 
(API) as a powdered raw material is 
not always practical or possible and 
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thus commercially available tablets 
and capsules are often used in 
compounding oral liquids. These solid 
dosage forms however contain many 
excipients, which although compatible 
in the solid state have the potential to 
interact both in solution/suspension, 
adversely affecting the potency of the 
active ingredient and thus impacting 
on the shelf life of the compounded 
oral liquid. There are also certain 
tablets or capsule contents that 
should not be crushed (e.g. sustained-
release products). The pharmacist 
should consult the CMI to determine 
potential risks associated with 
crushing the solid dosage form. 
Further useful resources are detailed 
in previous articles in this series5,6 
and include the Clinical Monographs 
of the APF21,7 APAC guidelines for 
medication management in residential 
aged care facilities (Appendix F),8 
AMH Aged Care Companion,9 
Handbook of Drug Administration 
via Enteral Feeding Tubes,10 and 
electronic sources such as the list 
provided by the Institute for Safe 
Medication Practice.11 
Designing a 
suitable formula
Because of the presence of excipients 
in tablets and capsules and their 
potential ability to interact with the 
active drug in the liquid dosage form, 
there are problems associated with 
using stability data for an oral liquid 
made from powdered raw material 
and in making the assumption 
that oral liquids prepared from 
commercial tablets or capsules will 
have comparable stability and thus 
shelf life (see case study). 
A review in 2006 of 83 oral liquids 
extemporaneously prepared by 
modifying an existing commercial 
dosage form revealed that only 
7.2% of those compounded oral 
liquids exhibited stability concerns.13 
This review is a useful comprehensive 
summary of liquid dosage forms 
prepared from commercially available 
tablets/capsules and illustrates 
the low risk associated with these 
products, if cognisance is taken not 
only of the active ingredient but 
all those excipients present in the 
commercial dosage form. Pharmacists 
should be encouraged to use the 
following process to assist in the 
compounding of safe, stable oral 
liquids (Figure 1). 
In the absence of existing 
commercially available dosage forms 
or therapeutic alternatives in a suitable 
dosage form, a compounded oral 
liquid is best prepared by searching for 
a suitable formula. It is important that 
the stability of these compounded 
oral liquids is evaluated by methods 
of analysis that are ‘stability-
indicating’.14 Examples of journals 
containing stability-indicating methods 
of analysis include the Journal of 
Pharmacy Practice and Research, the 
International Journal of Pharmaceutical 
Compounding, and the Journal of 
American Health-System Pharmacists. 
However, a suitable search engine will 
provide results from a wider range of 
journals. For example, the following 
are available online (free access):
• Medline – 
www.ncbi.nlm.nih.gov/pubmed
• Google scholar – 
http://scholar.google.com.au/
schhp?hl=en&tab=ws
Useful texts include Allen’s 
Compounded Formulations,15 
Paediatric Drug Formulations,16 
and Stability of Compounded 
Formulations.17 However, it is 
important to check whether there is 
evidence for the stability of these 
formulations. Should no suitable 
formula be available in the literature, 
the pharmacist may design a formula 
from first principles. Appropriate 
excipients and methods of preparation 
are detailed below. 
Excipients
Excipients used in extemporaneous 
oral liquids commonly include 
suspending agents/viscosity 
enhancers, sweeteners and 
preservatives. They may also contain 
flavours, colours and buffers. 
Commercial liquid vehicles are 
available that contain a combination 
of sweeteners, flavours, viscosity 
enhancers/suspending agents 
and preservatives (contact your 
local pharmaceutical supplier for 
details). Some contain non-nutritive 
sweeteners and are therefore suitable 
for diabetic patients. It is not always 
necessary to colour a product. If a 
colouring agent is used, it should 
match the flavour (e.g. red for cherry) 
and should be used in minimal 
quantities to produce light-moderate 
density colours. The TGA has a 
recently updated list of colourings 
Case study: Caution 
when modifying 
existing formulae.
A study investigating the stability 
of an isoniazid (INH) liquid 
prepared using commercially 
available tablets and a British 
Pharmaceutical Codex (BPC) 
formula showed significant 
degradation of the INH (≥10% 
after three days at both 4 and 
25ºC), whereas the control (using 
pure INH powder) retained the 
desired stability of >90% after 
30 days, as specified in the BPC, 
under identical conditions.12 A 
replicate control formulation 
spiked with lactose (an excipient 
present in the commercial 
tablets), produced similar 
degradation profiles to that of 
the compounded oral liquid. INH 
is susceptible to hydrolysis and 
oxidation and is known to interact 
with reducing sugars (e.g. lactose) 
to form hydrazones. Although the 
BPC claimed 28 days stability 
for the extemporaneously 
prepared INH mixture, the use 
of INH powder, as opposed 
to INH tablets, was specified. 
This highlights the importance 
of considering not only the 
stability of the active drug but 
also the potential for interaction 
with excipients when modifying 
existing formulae.
Figure 1. Compounding 
medicines for children
Is there a suitable commercially 
available product?
Is there a therapeutic alternative 
available in a suitable dosage form?
Is there a published formula for a 
compounded oral liquid?
• Compendia
• Journals
• Reference Texts
Design a formula from first principles.
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permitted in medicines for oral use.18 
Mixtures may be required to be 
buffered to an optimum pH, or pH 
might need to be taken into account 
when using certain preservatives 
such as benzoic acid solution which 
requires an acidic pH to be effective.
Many stability studies are available in 
the literature that utilise commercial 
liquid vehicles, thereby making them 
a convenient resource, especially 
since various practice settings may 
not hold a wide variety of excipients in 
stock. If the commercial liquid vehicle 
is not suitable, and a formula for a 
compounded oral liquid supported 
by a stability-indicating method of 
analysis is not available, see Table 1 
for a general formula (adapted 
from the APF).7
Table 1. General formula for a 
compounded oral liquid
Ingredient Amount
API qs
Suspending agent qs* (APF21 – p48)
Sweetener/flavour qs* (APF21 – p55)
Preservative/
preservative 
solution
qs* (APF21 – p54)
Purified water to 100 mL
*See	APF21	for	appropriate	concentrations	of	excipients.
Method
Since most oral liquids will be 
prepared using a commercially 
available solid dosage form (tablet 
or capsule) which may not readily 
dissolve in water-based vehicles, a 
general method for preparing oral 
suspensions is described. Particle size 
reduction followed by the adequate 
wetting of solids are important 
steps in the preparation of a good 
suspension.
1. Crush the tablets in a dry mortar 
to a fine powder. For capsules, 
carefully open the capsules and 
empty the contents. 
2. The fine powder should then be 
wetted with a minimum amount 
(i.e. enough to produce a thick 
paste) of a suitable wetting agent 
(e.g. glycerin) or a portion of 
the vehicle. 
3. After the preparation of a thick 
paste, the vehicle and any other 
excipients should be added with 
constant stirring.
4. The preparation should then be 
transferred to an airtight medicine 
bottle with a child-resistant cap 
and appropriately labelled. Should 
the active drug or any of the 
excipients be sensitive to light, 
a coloured medicine bottle is 
recommended (note that many 
colouring and flavouring agents 
are sensitive to light). 
Packaging and storage
Oral liquids should be stored in an 
airtight container with a child-resistant 
cap. Should the active drug or other 
excipients be sensitive to light, 
a coloured medicine bottle should be 
used. In the absence of any published 
stability data, APF21 recommends 
an expiry date 28 days from the date 
of manufacture.7 Oral liquids should 
be stored at less than 25ºC unless 
otherwise specified. 
Labelling
Compounded products are to be 
labelled according to regulatory 
requirements19 and should include the 
approved pharmacopoeial name (where 
applicable) and the name and strength 
of any preservatives used. The label 
must also be in accordance with the 
relevant state law.7 A complete list 
of ingredients and their amounts/
proportions should be included when 
non-pharmacopoeial products are 
prepared. Ancillary labels should be 
used to indicate specific storage 
conditions, provide an expiry date and 
indicate specific usage conditions. 
Containers should always be labelled 
SHAKE THE BOTTLE to ensure even 
distribution of the drug content 
throughout the liquid vehicle to ensure 
an accurate dose is administered. 
Quality control and 
self-inspection
The pharmacist is responsible 
for ensuring the quality of 
extemporaneously prepared products, 
and should verify that products are 
prepared according to documented 
procedures and meet product 
specifications before release to the 
patient.7 Self-inspections should also 
be conducted at regular intervals 
to identify areas for improvement 
and the resulting actions should 
be documented.7
solutions through compounding
Counselling and 
instructions for carers
• Store the oral liquid as per 
instructions. 
• Discard the preparation after the 
expiry date (e.g. after 28 days, 
unless otherwise specified), and 
if the recommended storage 
temperature is 2–8ºC do not freeze.
• Do not remove all or part of the oral 
liquid from its original container 
as storage in a coloured medicine 
bottle will protect the active drug, 
if necessary, from light.
• SHAKE WELL before use to 
ensure that the patient receives an 
accurate dose.
Key learning points
• Pharmacists should determine 
whether commercial tablets/
capsules can be used in 
the preparation of oral 
compounded liquids.
• Pharmacists should consult 
reputable sources when 
compounding oral liquids 
including compendia (e.g. APF21) 
and journals.
• Due to the potential for interactions 
of multiple ingredients, KEEP 
IT SIMPLE and reduce the 
number of ingredients in oral 
compounded liquids.
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1. Oral liquids are still required 
to be compounded by 
pharmacists due to:
a) Paediatric patients being able to 
swallow tablets and capsules.
b) The lack of availability of 
commercially available oral liquids.
c) The physicochemical stability of 
the active drug and the excipients.
d) Increased financial viability to 
the pharmaceutical industry of 
manufacturing these dosage 
forms.
e) b and c.
2. Given the following formula 
from the APF for baclofen 
suspension CF-5 mg/mL 
– what is the role of the 
glycerin in the formula?
Baclofen 500 mg
Glycerin 4 mL
Methylcellulose 
mucilage APF
25 mL
Compound 
hydroxybenzoate 
solution
0.8 mL
Syrup APF to 100 mL
a) Active drug.
b) Vehicle.
c) Thickener/suspending agent.
d) Wetting agent.
e) Preservative.
3. Given the formula from the 
APF for propranolol mixture 
CF-5 mg/mL – rationalise why 
sodium benzoate is able to be 
used as a preservative:
Propranolol 
hydrochloride
500 mg
Citric acid 
monohydrate
1 g
Sodium benzoate 100 mg
Syrup 40 mL
Purified water to 100 mL
 
a) Sodium benzoate is the sodium 
salt of benzoic acid and is water 
insoluble.
b) The pH of the mixture is within 
an acceptable range for the 
preservative to be effective.
c) Citric acid is included as a buffer to 
maintain the pH of the mixture in 
an acceptable range (acidic).
d) b and c.
e) a, b and c.
Questions  A score of 3 out of 4 attracts three quarters of a credit point.
4. Labelling and storage 
requirements for orally 
compounded liquids are as 
follows:
a) Storage need not be in an airtight 
container.
b) Storage should be at less than 
35 ºC unless otherwise stated.
c) Labels are required to include only 
the name of the preservative.
d) Storage of all oral liquids should be 
in an amber bottle.
e) Labelling should always include 
SHAKE THE BOTTLE to ensure 
even distribution of the active 
drug throughout the mixture 
and that the patient receives an 
accurate dose.
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